Researchers at the University of Sydney have developed experimental nose drops that enhance learning and memory in aged mice while also preventing memory loss in a mouse model of Alzheimer’s disease. The treatment uses mRNA technology similar to that developed for use in COVID-19 vaccines.
The research, from the laboratory of Professor Greg Neely at the Charles Perkins Center, will lead to a new way to treat diseases of the brain, allowing for the development of medicines that target major neurological diseases, including neurodegeneration, stroke, traumatic brain injury and rare genetic and developmental diseases.
“If we can proceed quickly to clinical trials in humans, this approach could represent a world-first noninvasive delivery system to treat Alzheimer’s that bypasses the blood-brain barrier,” Neely said.
